Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial.

Tr, Klumpp; Mangan, Kenneth F.; Goldberg, Stuart L.; Pearlman, Eugene; Macdonald, John S.

doi:10.1200/jco.1995.13.6.1323

Cited by 178 publications

(146 citation statements)

References 19 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Various studies have evaluated the efficacy of using G-CSF in comparison to either placebo 11,16,17 or observation. 10,[18][19][20][21][22][23][24][25][26][27][28][29][30] These studies are summarized in Tables 1-3. Most of the studies involved patients with hematological malignancies (leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple myeloma), with some also enrolling patients with nonhematological malignancies.…”

Section: Review Of Literature: Autologous Transplantationmentioning

confidence: 99%

“…Most of the studies involved patients with hematological malignancies (leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple myeloma), with some also enrolling patients with nonhematological malignancies. 10,17,[20][21][22]24,25,27,29,30 Two studies specifically evaluated breast cancer patients undergoing autologous transplantation. 22,25 Most of the studies used filgrastim as a form of G-CSF, whereas three studies used lenograstim at either 263 mg per day 26 or at 150 mg/m 2 per day.…”

Section: Review Of Literature: Autologous Transplantationmentioning

confidence: 99%

“…G-CSF was administered on the basis of the patients' body weight in most studies at 5 mg/kg per day as either i.v. infusion or SQ injection 10,16,[18][19][20]22,[24][25][26]28,30 or at 10 mg/kg per day i.v. or SQ.…”

Section: Review Of Literature: Autologous Transplantationmentioning

confidence: 99%

“…[5][6][7][8][9] The use of G-CSF after HSCT accelerates granulocyte engraftment and recovery by 1-6 days in comparison with control. [10][11][12][13] However, most of the studies have been carried out on small numbers of patients and have varied significantly in patient demographics, G-CSF dosage regimen and other factors affecting outcomes. Overall, there is no consensus on the optimal use of G-CSF after high-dose chemotherapy followed by HSCT.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Optimal use of G-CSF administration after hematopoietic SCT

Trivedi

Martinez

Corringham³

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Review Of Literature: Autologous Transplantationmentioning

confidence: 99%

Section: Review Of Literature: Autologous Transplantationmentioning

confidence: 99%

Section: Review Of Literature: Autologous Transplantationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Optimal use of G-CSF administration after hematopoietic SCT

Trivedi

Martinez

Corringham³

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

“…43 Patient characteristics and one patient (UPN 108) who received GM-CSF Seventy patients were transplanted on this protocol between 7 g/kg/day starting at day +1.…”

Section: Menopausal Status At Diagnosismentioning

confidence: 99%

Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment

Goldberg

Magdalinski

et al. 1997

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Seventy women with high-risk stage II (n = 10), IIIA Breast cancer remains an important source of morbidity and mortality among women, with an estimated 46 000 deaths annually in the United States alone. 1 Despite extensive (n = 12), IIIB (n = 11), or IV (n = 37) breast cancer research, recently published studies continue to report zero received cyclophosphamide 6000 mg/m 2 , etoposide or near-zero long-term progression-free survival rates 2400 mg/m 2 , and carboplatin 1200 mg/m 2 followed by among women with metastatic disease 2-7 and less than 50% infusion of autologous hematopoietic stem cells (AHSC).long-term survival among women with locoregional disWomen with high-risk stage II disease had eight or ease. 8,9 For example, a recently published 20-year followmore involved axillary lymph nodes (n = 9) or axillary up analysis 8 of a major adjuvant chemotherapy trial and breast relapse following lumpectomy, chemoreported 37% long-term progression-free survival among therapy, and radiation therapy (n = 1). Women with women with one to three involved axillary lymph nodes, measurable stage III or stage IV disease were required 26% progression-free survival among women with four to to demonstrate complete or partial response to conven-10 axillary nodes involved, and no long-term progressiontional-dose chemotherapy prior to transplant. The overfree survivors among women with more than 10 involved all (complete plus partial) response rate for the 31 nodes. Similarly, a recently reported large chemotherapy patients not in complete remission at the time of transtrial in women with previously untreated metastatic disease plant was 55%. With a median follow-up of 545 days, reported a 0% survival rate at less than 5 years. 7 the 2-year actuarial progression-free survival rates forDisappointing long-term results with conventional-dose patients with stage II, IIIA, IIIB and IV are 86, 75, 42 therapy, as well as both controlled and uncontrolled studies and 13%, respectively. Factors independently predictive suggesting a chemotherapeutic dose-response relationship of longer progression-free survival by multivariate for breast cancer within conventional dose ranges 7-9 have analysis included lower stage disease, status of disease led to the introduction of high-dose therapy (HDC) folat transplant (in CR vs not in CR), and positive estrogen lowed by rescue with autologous blood or marrow-derived receptor status. Factors predictive of more rapid neuhematopoietic stem cells (AHSC) in women with metastatic trophil engraftment by multivariate analysis included or high-risk non-metastatic breast cancer. 10-33 post-transplant administration of hematopoietic growthWe elected to study the combination of high-dose cyclofactors, greater number of infused CFU-GM, mobilizphosphamide, etoposide, and carboplatin (CEC) for a phase ation with G-CSF or cyclophosphamide/G-CSF (vs II study in this patient population for several reasons: (1) mobilization with GM-CSF or no mobilization), andThe efficacy of high-dose alkylating agent-based c...

show abstract

Recovery of leukocyte function after super-high-dose chemotherapy with peripheral blood stem cell transplantation in testicular cancer patients

et al. 1997

View full text Add to dashboard Cite

Leukocyte functions (superoxide production and phagocytosis) were evaluated in patients with testicular cancer who had undergone super-high-dose chemotherapy (SHDT) with peripheral blood stem cell transplantation (PBSCT). In 5 patients with advanced or relapsed testicular cancer who received 8 cycles of SHDT with PBSCT, we measured superoxide production activity by phorbol myristate acetate (PMA) stimulation, as well as phagocytic activity using latex particles before and after PBSCT. The median time to reach a leukocyte count of > >1,000/ml was 9 days after PBSCT. Superoxide production activity was significantly decreased on day 7 compared with the pre-chemotherapy level. However, it recovered by day 12 and sustained such a level thereafter. Phagocytic activity was within the normal range on day 7 but declined slightly on days 12 and 21 compared with the pre-chemotherapy level. Our results indicate that leukocyte function and leukocyte count recover promptly following PBSCT and that PBSCT is a safe and convenient adjunctive therapy after SHDT for patients with advanced testicular cancer. Int.

show abstract

Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial.

Cited by 178 publications

References 19 publications

Optimal use of G-CSF administration after hematopoietic SCT

Optimal use of G-CSF administration after hematopoietic SCT

Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment

Recovery of leukocyte function after super-high-dose chemotherapy with peripheral blood stem cell transplantation in testicular cancer patients

Contact Info

Product

Resources

About